Small Cell Lung Cancer
Conditions
Brief summary
This study aimed to explore the efficacy and biomarker explanation of IBI-322 Plus Lenvatinib on extensive stage small cell lung cancer who failed from first line PD-(L)1 inhibitors.
Interventions
DRUGIBI-322 Plus Lenvatinib
IBI322 is based on the 3+3 model, with a dose ascent starting from 10mg
Sponsors
Hunan Province Tumor Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Eligible subjects selected for this study must meet all of the following criteria: 1. Sign written informed consent before implementing any trial-related procedures; 2. Age ≥18 years old and ≤75 years old; 3. No limit on the gender; 4. Patients with extensive stage SCLC diagnosed by pathology (as staged by the American Veterans Lung Cancer Association (VALG)), who do not have an imaging response during first-line treatment with PD-(L)1 inhibitors, or who progress after imaging reactions on first-line therapy (the most recent regimen prior to enrollment must contain PD-(L)1 inhibitors); 5. According to the Response Evaluation Criteria for Solid Tumors (RECIST V1.1), there must be at least one lesion that can be measured by imaging. Lesions located within the radiation field of previous radiation therapy can be considered as measurable lesions if progress is confirmed; 6. ECOG score 0-1 points; 7. Expected survival time\> 3 months; 8. Sufficient organ function, subjects need to meet the following laboratory indicators: <!-- --> 1. The absolute value of neutrophils (ANC) ≥1.5x109/L when no granulocyte colony-stimulating factor is used in the past 14 days; 2. In the case of no blood transfusion in the past 14 days, platelets ≥100×109/L; 3. In the past 14 days without blood transfusion or erythropoietin, hemoglobin\>9g/dL; 4. Total bilirubin≤1.5×upper limit of normal (ULN); 5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) within ≤2.5×ULN (subjects with liver metastases are allowed to have ALT or AST ≤5×ULN); 6. Serum creatinine ≤1.5×ULN and creatinine clearance rate (calculated by Cockcroft-Gault formula) ≥50ml/min; 7. Good coagulation function, defined as International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 times ULN; 8. Normal thyroid function is defined as thyroid-stimulating hormone (TSH) within the normal range. If the baseline TSH is out of the normal range, subjects whose total T3 (or FT3) and FT4 are within the normal range can also be included in the group; 9. Myocardial enzyme spectrum is within the normal range (for example, simple laboratory abnormalities that are judged by the investigator to be of no clinical significance are also allowed to be included in the group).
Exclusion criteria
* Patients with contraindication of chemotherapy Pregnant or breast feeding women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR | 12 weeks | Defined as the proportion of subjects in complete remission (CR) and partial remission (PR) to the total subjects |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | 1year | Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first) |
| OS | 1 year | Defined as the time from the start of treatment to the death of the subject due to any cause. |
Countries
China
Contacts
Primary ContactYongchang C Zhang, MD
Backup ContactNong C Yang, MD
Outcome results
None listed